Professor | Weiqiang Lu | Asia Growth Partners

Name

Weiqiang Lu

Contact Information

wqlu@bio.ecnu.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	East China Normal University
Faculty	Life Sciences
Academic Background & Achievements	2004-2008 Bachelor's Degree: East China University of Science and Technology 2008-2013 PhD: East China University of Science and Technology Published over 50 research papers as first or corresponding author Applied for 20 domestic patents, granted 9
Work Experience	2013-2017 Assistant Researcher, East China Normal University, School of Life Sciences 2018-2022 Associate Researcher, East China Normal University, School of Life Sciences 2022-present Researcher, East China Normal University, School of Life Sciences
Awards	2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award 2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize 2020: 'Internet+' Outstanding Instructor for College Students' Innovation and Entrepreneurship 2021: 5th National Matrix Biology Conference Young Report Second Prize

University/Lab Affiliation and Title

East China Normal University

Faculty

Life Sciences

Academic Background & Achievements

Work Experience

2013-2017 Assistant Researcher, East China Normal University, School of Life Sciences
2018-2022 Associate Researcher, East China Normal University, School of Life Sciences
2022-present Researcher, East China Normal University, School of Life Sciences

Awards

2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award
2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize
2020: 'Internet+' Outstanding Instructor for College Students' Innovation and Entrepreneurship
2021: 5th National Matrix Biology Conference Young Report Second Prize

Areas of Focus	GPCR and tumor immune regulation Development of innovative anti-tumor drugs targeting GPCR
Publications	PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu et al., 2023 Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Weiqiang Lu et al., 2024 Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Weiqiang Lu et al., 2024

Areas of Focus

GPCR and tumor immune regulation
Development of innovative anti-tumor drugs targeting GPCR

Publications

PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu et al., 2023
Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Weiqiang Lu et al., 2024
Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Weiqiang Lu et al., 2024

Gpcr Tumor Immune Regulation Molecular Mechanisms Drug Development Oncology Pharmacology Cell Signaling Receptor Therapeutics

Songcheng Zhu - Tongji University

Min Qian - East China Normal University

Wang Zi - Central South University

View All

Personal Information